Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.24.1.u1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating Activities:    
Net loss $ (6,494) $ (8,992)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization [note 4] 57 58
Stock-based compensation [note 8[c], note 8[e], note 8[f] and note 8[g]] 1,288 1,085
Accrued interest on SVB convertible debt [note 7] 318 300
Accretion of discount on modification of debt 161  
Change in fair value of contingent consideration [note 5 and note 6] 52  
Changes in operating assets and liabilities:    
Grant receivable [note 3] 111 16
Prepaid expenses and other assets (19) 886
Accounts payable (245) (597)
Accrued liabilities other 686 296
Accrued clinical liabilities 245 (366)
Accrued compensation (1,447) (931)
Lease obligation [note 9] (1) (58)
Net cash used in operating activities (5,288) (8,303)
Financing Activities:    
Proceeds from exercise of warrants   77
Net cash provided by financing activities 56,110 47
Effect of exchange rate changes on cash   (1)
Net increase/(decrease) in cash, cash equivalents and restricted cash 50,822 (8,257)
Cash, cash equivalents and restricted cash at beginning of the period 15,596 24,821
Cash, cash equivalents and restricted cash at end of the period 66,418 16,564
November 2022 Private Placement [Member]    
Financing Activities:    
Financing costs relating to November 2022 private placement   $ (30)
February 2024 Private Placement [Member]    
Financing Activities:    
Proceeds from February 2024 private placement, net of issuance costs $ 56,110